Intestinal Research

Original Article

IBD

Sarcopenia is common in ulcerative colitis and correlates with disease activity: Pardhu B Neelam, Rimesh Pal, Pankaj Gupta, Anupam K Singh, Jimil Shah, Harshal S Mandavdhare, Harjeet Singh, Aravind Sekar, Sanjay K Bhadada, Usha Dutta, Vishal Sharma; Intest Res 2024;22(2):162-171. Published online January 22, 2024; DOI: https://doi.org/10.5217/ir.2023.00090

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Association of sarcopenia with disease severity in ulcerative colitis (UC) is not clearly defined. We planned to estimate the prevalence of sarcopenia in patients with UC as per the revised definition and its relation with the disease severity.
Methods
A cross-sectional assessment of sarcopenia in patients with UC was performed. Disease activity was graded according to complete Mayo score. Hand grip strength was assessed with Jamar hand dynamometer, muscle mass using a dual energy X-ray absorptiometry scan, and physical performance with 4-m walk test. Sarcopenia was defined as a reduction of both muscle mass and strength. Severe sarcopenia was defined as reduced gait speed in presence of sarcopenia.
Results
Of 114 patients (62 males, mean age: 36.49±12.41 years), 32 (28%) were in remission, 46 (40.4%) had mild-moderate activity, and 36 (31.6%) had severe UC. Forty-three patients (37.7%) had probable sarcopenia, 25 (21.9%) had sarcopenia, and 14 (12.2%) had severe sarcopenia. Prevalence of sarcopenia was higher in active disease (2 in remission, 6 in active, and 17 in severe, P<0.001). Of 14 with severe sarcopenia, 13 had severe UC while 1 had moderate UC. On multivariate analysis, lower body mass index and higher Mayo score were associated with sarcopenia. Of 37 patients with acute severe colitis, 16 had sarcopenia. Requirement of second-line therapy was similar between patients with and without sarcopenia. On follow-up (median: 18 months), there was a non-significant higher rate of major adverse events in those with sarcopenia (47.4% vs. 33.8%, P=0.273).
Conclusions
Sarcopenia and severe sarcopenia in UC correlate with the disease activity.

Citations

Citations to this article as recorded by

Prevalence and outcome of sarcopenia in patients with inflammatory bowel disease: a follow-up study
Vikram Dharap, Devendra Desai, Philip Abraham, Tarun Gupta, Pavan Dhoble, Nirad Mehta, Jagdish Modhe
Intestinal Research.2025;[Epub] CrossRef
Prevalence and impact of sarcopenia in patients with inflammatory bowel diseases: A prospective cohort study
Solène Dermine, Thomas Bazin, Fatimé Adam Hassan, Johanna Bettolo, Lore Billiauws, Justine Bourdillel, Clément Bresteau, Olivier Corcos, Myriam El khatib, Ashiq Mohamed Gouse, Coralie Hutinet, Alexandre Nuzzo, Francisca Joly
Clinics and Research in Hepatology and Gastroenterology.2025; 49(4): 102555. CrossRef
Metabolic musculoskeletal disorders in patients with inflammatory bowel disease
Young Joo Yang, Seong Ran Jeon
The Korean Journal of Internal Medicine.2025; 40(2): 181. CrossRef
Sarcopenia and frailty in inflammatory bowel disease: Emerging concepts and evidence
Pardhu B Neelam, Alka Sharma, Vishal Sharma
JGH Open.2024;[Epub] CrossRef
Utility of SARC‐F for screening for sarcopenia in ulcerative colitis
Pardhu B. Neelam, Vishal Sharma
Nutrition in Clinical Practice.2024; 39(5): 1270. CrossRef
Response to “Utility of SARC‐F for screening for sarcopenia in ulcerative colitis”
Ilkay Ergenc, Chasan Ismail Basa, Alper Uzum, Sevval Sahin, Haluk Tarık Kani, Rahmi Aslan, Aslı Tufan, Özgür Kasımay, Özlen Atuğ, Yeşim Özen Alahdab
Nutrition in Clinical Practice.2024; 39(5): 1272. CrossRef
Sarcopenia and low prognostic nutritional index as markers of disease activity in patients with inflammatory bowel disease and predictors of poor outcome: a cohort longitudinal study
Mirella Sherif, Rabab Fouad, Tamer Elbaz, Maryse Awadalla, Omnia Tantawi, Mohamed Negm, Dalia Abd El-kareem, Ibrahim Naguib, Hany Shehab, Hedy A. Badary
Egyptian Rheumatology and Rehabilitation.2024;[Epub] CrossRef

5,092 View
280 Download
6 Web of Science
7 Crossref

Brief Communication

Infection

Gastrointestinal histoplasmosis: a case series from a non-endemic region in North India: Harshal S Mandavdhare, Jimil Shah, Kaushal K Prasad, Roshan Agarwala, Vikas Suri, Savita Kumari, Usha Dutta, Vishal Sharma; Intest Res 2019;17(1):149-152. Published online October 16, 2018; DOI: https://doi.org/10.5217/ir.2018.00111

PDF PubReader ePub

Citations

Citations to this article as recorded by

Gastrointestinal Histoplasmosis: A Descriptive Review, 2001–2021
Bassey E. Ekeng, Asa E. Itam-Eyo, Iriagbonse I. Osaigbovo, Adilia Warris, Rita O. Oladele, Felix Bongomin, David W. Denning
Life.2023; 13(3): 689. CrossRef
Isolated Colonic Histoplasmosis in Patients Undergoing Immunomodulator Therapy: A Systematic Review
Faisal Inayat, Gul Nawaz, Arslan Afzal, Maleeha Ajmal, Marjan Haider, Muhammad Sarfraz, Zaka Ul Haq, Sobaan Taj, Rizwan Ishtiaq
Journal of Investigative Medicine High Impact Case Reports.2023;[Epub] CrossRef
An Unusual Discovery of Multi-Opportunistic Organisms in Gastrointestinal Biopsies of a Patient With Acquired Immunodeficiency Syndrome and Infectious Colitis
Chirag Patel, Patricia Le, Malik Salman, Stephen Cavalieri, Joyce Kovar
Cureus.2023;[Epub] CrossRef
A case report of gastrointestinal histoplasmosis in a patient treated with infliximab
Berta Oliveras, Marc Albert, Carme López, Esther Fort, Laia Peries, Laia Gutiérrez, David Busquets, Hugo Uchima, Xavier Aldeguer, Virginia Piñol
Clinical Journal of Gastroenterology.2021; 14(2): 690. CrossRef
A case of gastrointestinal histoplasmosis with esophageal involvement
Mathew Finniss, Paul Lewis, James Myers, Lamis Ibrahim, Paras Patel
Clinical Journal of Gastroenterology.2020; 13(2): 173. CrossRef
Ileocecal thickening: Clinical approach to a common problem
Roshan Agarwala, Abhi K Singh, Jimil Shah, Harshal S Mandavdhare, Vishal Sharma
JGH Open.2019; 3(6): 456. CrossRef

8,860 View
189 Download
7 Web of Science
6 Crossref

First
Prev
Page of 1
Next
Last

Search